Swiss Takeover Board confirms Absence of an Obligation to make a Public Takeover Offer in connection with planned Enbiotix Merger
Polyphor AG / Key word(s): Merger
Allschwil, Switzerland, October 15, 2021
Decision of the Takeover Board
In its decision of October 13, 2021 (published on www.takeover.ch), the Takeover Board has decreed the following:
1. It is hereby determined that the proposed transaction set out in the presented files does not trigger an obligation to make an offer within the meaning of art. 135 para. 1 sentence 1 of the FinMIA for EnBiotix, Inc., Wired Holding Investment Corp., Apeiron Holdings Limited, Polyphor AG, James J. Collins, Trustees of Boston University, Jeffrey D. Wagner, NAEJA Pharmaceutical, Inc., YPOP II LLC and Sanford Biosciences, LLC.
2. Polyphor AG is required to publish the opinion of its Board of Directors together with the operative part of this decision (Dispositiv) and a reference to the right of objection pursuant to art. 58 TOO.
3. This decision shall be published on the website of the Takeover Board following the publication of Polyphor AG in accordance with the second paragraph of this decision.
4. The fee payable by EnBiotix, Inc. amounts to CHF 20,000.
A qualified shareholder may file an objection against the Takeover Board's decision. The objection must be filed with the Takeover Board (Stockerstrasse 54, 8002 Zurich; fax: +41 44 283 17 40) within five trading days from the date of publication of the decision of the Takeover Board. The first trading day after the publication of the decision of the Takeover Board on the Takeover Board's website will be the first day of the filing period. The objection must contain a formal request, summary reasons and proof of the qualified participation.
For further information please contact:
End of ad hoc announcement
|Phone:||+41 61 567 1600|
|Fax:||+41 61 567 1601|
|Listed:||SIX Swiss Exchange|
|EQS News ID:||1240950|
|End of Announcement||EQS Group News Service|